Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:57:19 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:RHHBY from 2023-05-04 to 2024-05-03 - 53 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-18 16:35U:RHHBYNews ReleaseFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
2024-04-17 02:06U:RHHBYNews ReleaseGenentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
2024-04-15 01:10U:RHHBYNews ReleaseGenentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
2024-04-10 01:00U:RHHBYNews ReleaseRoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
2024-03-12 02:00U:RHHBYNews ReleaseRoche showcases new navify(TM) digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS Superscript 1 2024
2024-03-12 02:00U:RHHBYNews ReleaseRoche showcases new navify(TM) digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS Superscript 1 2024
2024-02-25 14:00U:RHHBYNews ReleaseNew England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
2024-02-16 11:15U:RHHBYNews ReleaseFDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
2024-02-13 01:00U:RHHBYNews ReleaseRoche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics
2024-02-01 01:05U:RHHBYNews ReleaseNew Long-Term Data for Genentech ¢ € ™s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
2024-01-03 07:00U:RHHBYNews ReleaseRemix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing
2023-12-19 09:40U:RHHBYNews ReleaseFDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
2023-12-19 01:00U:RHHBYNews ReleaseRoche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
2023-12-19 01:00U:RHHBYNews ReleaseRoche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
2023-12-14 09:00U:RHHBYNews ReleaseRoche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
2023-12-10 19:30U:RHHBYNews ReleaseNew Data for Genentech ¢ € ™s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
2023-12-09 11:30U:RHHBYNews ReleaseNew Data Reinforce the Benefit of Early Preventative Treatment With Genentech ¢ € ™s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
2023-12-08 11:45U:RHHBYNews ReleaseGenentech ¢ € ™s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
2023-12-08 11:45U:RHHBYNews ReleaseGenentech ¢ € ™s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
2023-12-05 01:00U:RHHBYNews ReleaseGenentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
2023-11-21 09:00U:RHHBYNews ReleaseGenentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
2023-11-20 01:00U:RHHBYNews ReleaseRoche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges
2023-10-27 01:10U:RHHBYNews ReleaseFDA Approves Genentech ¢ € ™s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
2023-10-26 01:00U:RHHBYNews ReleaseRoche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses
2023-10-23 01:00U:RHHBYNews ReleaseRoche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
2023-10-18 01:00U:RHHBYNews ReleaseGenentech ¢ € ™s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
2023-10-13 09:30U:RHHBYNews ReleaseLate-Breaking Data for Genentech ¢ € ™s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
2023-10-12 01:00U:RHHBYNews ReleaseNew Data for Genentech ¢ € ™s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
2023-10-11 02:00U:RHHBYNews ReleaseFirst-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech ¢ € ™s Ocrevus Effectively Manages Disease Activity
2023-10-11 02:00U:RHHBYNews ReleaseGenentech ¢ € ™s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
2023-10-10 01:00U:RHHBYNews ReleaseGenentech ¢ € ™s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
2023-10-04 01:00U:RHHBYNews ReleaseMajority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech ¢ € ™s Evrysdi Able to Sit Independently After 1 Year of Treatment
2023-10-02 01:00U:RHHBYNews ReleaseGenentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
2023-09-06 01:00U:RHHBYNews ReleaseFDA Accepts Application for Genentech ¢ € ™s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
2023-09-05 01:00U:RHHBYNews ReleaseEconomist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
2023-09-05 01:00U:RHHBYNews ReleaseEconomist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
2023-09-01 01:00U:RHHBYNews ReleaseGenentech ¢ € ™s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
2023-08-23 01:43U:RHHBYNews ReleaseGenentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
2023-08-17 01:00U:RHHBYNews ReleaseRoche launches a new addition to the cobas ‚ ® connection modules, the CCM Vertical, helping to improve laboratory efficiency
2023-08-08 01:00U:RHHBYNews ReleaseNew opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
2023-08-08 01:00U:RHHBYNews ReleaseNew opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
2023-08-03 01:00U:RHHBYNews ReleaseRoche expands long-term alliance with Sysmex
2023-07-20 01:00U:RHHBYNews ReleaseNew Clinical and Real-World Data for Genentech ¢ € ™s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
2023-07-19 09:39U:RHHBYNews ReleaseRoche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo
2023-07-13 01:00U:RHHBYNews ReleasePositive Phase III Results for Genentech ¢ € ™s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
2023-06-27 09:03U:RHHBYNews ReleaseRoche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making
2023-06-15 19:59U:RHHBYNews ReleaseFDA Approves Genentech ¢ € ™s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023-06-09 08:45U:RHHBYNews ReleaseNew Data Show Genentech ¢ € ™s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2023-06-08 08:00U:RHHBYNews ReleaseDevelopment in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions
2023-06-08 08:00U:RHHBYNews ReleaseDevelopment in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions
2023-05-17 01:00U:RHHBYNews ReleaseGenentech ¢ € ™s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
2023-05-17 01:00U:RHHBYNews ReleaseRoche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab
2023-05-09 01:00U:RHHBYNews ReleaseFDA Accepts Application for Genentech ¢ € ™s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)